Insider Transactions in Q4 2020 at Bristol Myers Squibb CO (BMY)
Insider Transaction List (Q4 2020)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 31
2020
|
Nadim Ahmed EVP and President, Hematology |
SELL
Payment of exercise price or tax liability
|
Direct |
7,660
-16.46%
|
$474,920
$62.03 P/Share
|
Dec 31
2020
|
Nadim Ahmed EVP and President, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
14,946
+24.3%
|
-
|
Dec 31
2020
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,931
-15.08%
|
$739,722
$62.03 P/Share
|
Dec 31
2020
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,624
+20.68%
|
-
|
Dec 31
2020
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
13,257
-19.47%
|
$821,934
$62.03 P/Share
|
Dec 31
2020
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
25,866
+27.53%
|
-
|
Dec 02
2020
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,299
-5.49%
|
$80,538
$62.18 P/Share
|
Dec 02
2020
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,637
+10.02%
|
-
|
Dec 02
2020
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,087
-8.0%
|
$315,394
$62.18 P/Share
|
Dec 02
2020
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,792
+12.15%
|
-
|
Dec 02
2020
|
Nadim Ahmed EVP and President, Hematology |
SELL
Payment of exercise price or tax liability
|
Direct |
3,380
-9.66%
|
$209,560
$62.18 P/Share
|
Dec 02
2020
|
Nadim Ahmed EVP and President, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
6,594
+15.86%
|
-
|
Dec 02
2020
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
4,506
-9.65%
|
$279,372
$62.18 P/Share
|
Dec 02
2020
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
8,792
+15.84%
|
-
|
Dec 01
2020
|
Joseph Eid SVP,Head Glob. Medical Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
968
-18.06%
|
$60,016
$62.41 P/Share
|
Dec 01
2020
|
Joseph Eid SVP,Head Glob. Medical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
2,825
+34.52%
|
-
|
Nov 25
2020
|
Paul Von Autenried EVP, Chief Information Officer |
SELL
Open market or private sale
|
Direct |
3
-0.0%
|
$189
$63.5 P/Share
|
Nov 24
2020
|
Paul Von Autenried EVP, Chief Information Officer |
SELL
Open market or private sale
|
Direct |
20,000
-13.63%
|
$1,240,000
$62.75 P/Share
|
Nov 24
2020
|
Adam Dubow SVP,ChiefCompliance&EthicsOff. |
SELL
Open market or private sale
|
Direct |
900
-5.59%
|
$56,700
$63.39 P/Share
|
Nov 23
2020
|
Rupert Vessey EVP & President, Research |
SELL
Open market or private sale
|
Direct |
13,421
-26.14%
|
$818,681
$61.34 P/Share
|
Nov 19
2020
|
Rupert Vessey EVP & President, Research |
SELL
Open market or private sale
|
Direct |
57,591
-33.22%
|
$3,513,051
$61.28 P/Share
|
Nov 19
2020
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
52,213
+11.94%
|
$2,506,224
$48.03 P/Share
|
Oct 30
2020
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
2,859
-4.8%
|
$165,822
$58.45 P/Share
|
Oct 30
2020
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
5,804
+8.88%
|
-
|
Oct 30
2020
|
Nadim Ahmed EVP and President, Hematology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,291
-7.47%
|
$132,878
$58.45 P/Share
|
Oct 30
2020
|
Nadim Ahmed EVP and President, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
4,650
+13.16%
|
-
|